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S U M M A R Y
Background: Hepatitis C virus (HCV) is the causative agent of chronic liver diseases, which usually lead to
liver ﬁbrosis, liver cirrhosis, and hepatocellular carcinoma (HCC). Among the non-structural genes of
HCV, NS3 and NS5A play important roles in apoptosis. The NS3 and NS5A genes of HCV interact with the
p53 tumor suppressor gene differentially. The objective of this study was to analyze the interaction of
NS3 and NS5A genes of HCV genotype 3a with the p53 gene, subgenomic HCV replicons harboring NS3
and NS5A genes.
Methods: Huh-7 cell lines stably expressing NS3 and NS5A genes were generated. The stable cell lines
were conﬁrmed by Western blot, reverse transcriptase PCR, and immunoﬂuorescence assay. HCV NS3-
and NS5A-expressing cell lines were transfected with p53-expressing clone.
Results: NS3 and NS5A both interact with p53 by down-regulating the expression of the p53 gene. In
HCV subgenomic harboring cells, the interaction of NS3 and NS5A with p53 was observed consistently.
The suppression of p53 gene expression by NS3 and NS5A was observed signiﬁcantly as compared with
NS3- and NS5A-negative control Huh-7 cells.
Conclusion: It is concluded that both of the non-structural genes, NS3 and NS5A, of HCV play important
roles in the hepatocarcinogenesis of HCV by interacting directly or indirectly in different manners with
the p53 gene.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
nc-sa/3.0/).
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Hepatitis C virus (HCV) is the principal cause of post-
transfusion and public-acquired non-A, non-B hepatitis,1 and
belongs to the family Flaviviridae.2 It is a positive single-stranded
(SS) RNA virus with a genome 9600 nucleotides in length, which
encodes a polyprotein of nearly 3000 amino acids.3,4 The precursor
polyprotein is further processed into various structural proteins (C,
E1, and E2 p7) and non-structural proteins (NS2, NS3, NS4A, NS4B,
NS5A, and NS5B).5
The HCV serine viral protease is encoded by the NS3 gene,5
which consists of two important domains: the ﬁrst is a catalytic
domain (amino acids 1–180) present at the N-terminus, while the* Corresponding author. Tel.: +92 42 5293141; fax: +92 42 5293149.
E-mail address: Idrees.khan96@yahoo.com (M. Idrees).
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license (http://creativecommons.org/licenses/by-nc-sa/3.0/).second is an ATP-dependent RNA helicase (amino acids 181–631)
present at the C-terminus.6,7 The HCV NS3 protein is a
multifunctional protein and inhibits the host protein kinase A
(PKA)8 and protein kinase C (PKC).6,9 A main focus of research has
been the NS3 proteinase activity because it is necessary for HCV
replication, so it is considered the principal candidate for the
development of an antiviral drug.10
HCV NS5A is a viral regulatory protein that modulates viral RNA
replication and host processes by interacting directly and
indirectly with a variety of host regulatory factors.11 The exact
function of NS5A is still ambiguous, but it is considered that NS5A
plays an important role in regulating HCV replication.12
Apoptosis is possibly the most primordial response of a virally
infected cell, designed to thwart the spread of infection and protect
the organism as a whole. Whereas an acutely infecting virus needs
to prevent apoptosis of infected cells only long enough to produce
progeny virions, a persisting virus must have a means to suppressciety for Infectious Diseases. This is an open access article under the CC BY-NC-SA
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compartment of infected cells. The tumor suppressor protein
p53 is an attractive target for many viruses.13
Viral gene products target residues of the N terminus of p53
that are employed to interact with the transcriptional machinery of
cells.14 Most of the p53-interacting viral proteins are reported to
suppress p53 function.12 It has been reported that p53 forms a
complex with NS3 protein. A portion near the C-terminus of p53,
which has been reported to contain the oligomerization domain, is
important for complex formation with NS3. It has also been
reported that NS3 represses the transcription of p21 by modulating
the activity of p53.15 The HCV anti-apoptotic mechanism of the
viral protein NS5A involves the inhibition of the Kv2.1 K+ channel,
preventing hepatoma cell apoptosis in response to oxidative
stress.13 The interaction of some of these viral oncoproteins may
cause a sequestration in the p53 apoptotic pathway.12
The establishment of an HCV cell culture system based on a
particular molecular clone offers the opportunity of directly
evaluating the inactivation methods for HCV.16 The main aim of the
present study was to develop such a system; this would be a
valuable tool for the study of viral gene expression. We
successfully developed stable cell lines of NS3 and NS5A
subgenomic replicons of local HCV genotype 3a and studied their
relationships with apoptotic protein p53.
2. Methods
2.1. Complementary DNA synthesis and ampliﬁcation of NS3 and
NS5A genes
Chronically infected HCV-positive patients with genotype 3a
were identiﬁed from the Division of Molecular Virology and
Molecular Diagnostics, National Center of Excellence in Molecular
Biology (CEMB), Lahore, Pakistan. RNA was isolated from the HCV-
positive patients using an RNA isolation kit (Gentra, Life
Technologies, USA) in accordance with the kit protocol. The RNA
was reverse-transcribed using Moloney murine leukemia virus
reverse transcriptase (M-MLV RT; Invitrogen Life Technologies, CA,
USA). cDNA was further used for the ampliﬁcation of the NS3 and
NS5A genes using gene-speciﬁc primers. Primers were designed
using Primer3 software using GU294484.1 as a reference
sequence; restriction sites and Kozak sequences were added after
analysis on web and neb cutter. Primer sequences are shown in
Table 1.
2.2. Cloning of NS3 and NS5A genes in mammalian expression vector
The ampliﬁed gene with speciﬁc restriction sites was then
cloned into pcDNA3.1 (Invitrogen Life Technologies, CA, USA).
Plasmid pcDNA3.1/NS3 (full) encodes the NS3 protein. Construct
pcDNA3.1/NS5A (full) encodes the NS5A protein. BamHI and NotI
recognition sites were introduced by PCR into the individual genes
at the 50 and 30 ends, respectively. Genes were digested with
respective enzymes and subcloned into pcDNA3.1 (Invitrogen Life
Technologies, CA, USA). Each constructed plasmid expressingTable 1
List of primers for the individual genes of HCV genotype 3a, restriction sites, and
number of nucleotides each region ampliﬁes
Genes Primer sequence 50–30 Restriction
sites
No. of
nucleotides
ampliﬁed
NS3-IS GGCCGTGAGGTGTTGTTGG BamHI 1953
NS3-IAS TGGTTACTTCCAGATCGGCTG NotI
NS5A-IS AGCGACGATTGGCTACGTAC BamHI 1356
NS5A-IAS AGCAGACCACGCTCTGCTC NotIindividual HCV 3a genes was conﬁrmed through PCR, restriction
digestion, and by sequencing. Sequences of the NS3 (accession
number JX679463) and NS5A (accession number JX679462) genes
have been submitted to GenBank.
2.3. Cell culture and transfection
Huh-7 cell lines were grown and maintained in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) supplemented with 100 mg/ml
streptomycin, penicillin, and 10% fetal bovine serum (FBS; Sigma
Aldrich, USA) at 37 8C with 5% CO2 for the experimental work. Cells
were seeded in 6-well plates (5  105/well) and were further
cultured until the cells became 70–80% conﬂuent. When the cells
were conﬂuent up to 75% they were then transfected with 10 mg of
linearized pcDNA3.1/NS3 and pcDNA3.1/NS5A using lipofectamine
reagent (Invitrogen Life Technologies, CA, USA). After 6–8 h of
incubation, the transfection medium was changed with medium
containing 100 mg/ml of penicillin, streptomycin, and 10% FBS.
2.4. Extraction of RNA from cell lines (NS3, NS5A, and Huh-7) and
reverse transcriptase (RT)-PCR
For the conﬁrmation of successful transfection and expression
of NS3 and NS5A in Huh-7 cell lines, the total RNA was extracted
from Huh-7 cells using an RNA isolation kit (Gentra, Life
Technologies, USA) and reverse-transcribed to cDNA with the
corresponding antisense primers for each individual gene. For the
conﬁrmation of mRNA, the reverse-transcribed RNA for each gene
was further ampliﬁed using gene-speciﬁc primers (Table 1) with
Taq polymerase. All PCR products were run on a 1.2% agarose gel
and stained with ethidium bromide (0.5 mg/ml) and photographed
on a UV illuminator.
2.5. Protein extraction from Huh-7 and stably transfected cell lines,
and Western blotting
For protein expression analysis, Huh-7 cells were lysed after
72 h and protein was extracted from the total cell lysate. Cells were
pelleted down and washed with 1 phosphate buffered saline
(PBS) and centrifuged at 8000 rpm for 3 min. Next, 60 ml of protein
lysis buffer was added and vortexed for 5 s, and this was kept on ice
for 15 min. After 10 min, this was centrifuged at 13 000 rpm at 4 8C
for 15 min. Sixty micrograms of the extracted protein were loaded
onto a 10% sodium dodecyl sulfate polyacrylamide gel electropho-
resis (SDS-PAGE) gel and then shifted to a Hybond-C extra
nitrocellulose membrane and placed in a semi-dry blotting
apparatus (Bio-Rad) for 90 min at 16 V. The proteins on the
membrane were blocked with 5% skimmed milk solution for 1 h
after washing two times with (PBS–Tween), then incubated with
NS3 and NS5A gene-speciﬁc monoclonal antibodies (NS3-sc-69938
and NS5A-sc-57776) overnight. The primary antibodies were
detected using speciﬁc anti-mouse secondary antibody conjugated
to alkaline phosphatase (Sigma) at a dilution of 1:1000 by
incubating the blot for 1 h at room temperature. The blot was
washed three times with PBST and the membrane was then treated
with Nitro-blue tetrazolium and 5-bromo-4-chloro-30-indolypho-
sphate (NBT/BCIP) substrate for 15–30 min at 37 8C.
2.6. Immunoﬂuorescence assay
Huh-7 cell lines carrying the cloned NS3 and NS5A genes were
grown overnight on glass coverslips and were ﬁxed with 4% p-
formaldehyde at 20 8C. Fixed cells were blocked using 1% donkey
serum in 1 PBS. For the detection of NS3 and NS5A proteins, cells
were incubated with the respective gene-speciﬁc antibodies
(1:100). After 2 h, the cells were washed with PBS and incubated
Figure 1. The ampliﬁed genes of HCV genotype 3a: (a) NS3 (1956 bp), and (b) NS5A (1356 bp).
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ﬂuorescein isothiocyanate (FITC, 1:100; Chemicon). After washing,
the coverslips were mounted onto the glass slide and examined
under a ﬂuorescence microscope.
2.7. Generation/establishment of Huh-7 stable cell lines of NS3 and
NS5A of genotype 3a local isolate
Huh-7 cells were transfected with 10 mg of linearized plasmid
DNA construct (pcDNA3.1/NS3, pcDNA3.1/NS5A) as described in
detail above. At 72 h post-transfection, growing cells were split
into 60-mm culture dishes and cells underwent selection using
G418 sulfate (Gibco), initially at a concentration of 1 mg/ml for
approximately 5 weeks. The medium was changed after 72 h.
Colonies resisting G418 were selected and grown/ampliﬁed to
obtain stable cell lines. Cells expressing HCV genotype 3a NS3 and
NS5A proteins were conﬁrmed with RT-PCR, Western blot, and
immunoﬂuorescence assay.
2.8. Analysis of the potential interaction of NS3 and NS5A proteins
with p53 protein
To investigate the possible interaction of NS3 and NS5A
proteins of HCV genotype 3a with p53 protein, Huh-7 cells and
HCV replicon (NS3 and NS5A) harboring cells were transfected
with pcDNA3.1/myc-his/p53 plasmid, as described above. After
48 h of transfection, the cells were lysed and proteins were
extracted from the total cell lysate. Untransfected Huh-7 cells
served as control. Sixty micrograms of protein was run on a 10%
SDS-PAGE gel and transferred to a nitrocellulose membrane. TheFigure 2. (a) pcDNA3.1/NS3 protein coding construct, expressed proteins were examined using p53-speciﬁc monoclonal
antibody (sc-55476), followed by detection with speciﬁc second-
ary antibody. The level of protein expression was analyzed. Each
experiment was performed at least twice; although there was
slight variation, consistent results were seen.
3. Results
3.1. PCR ampliﬁcation of viral NS3 and NS5A genes
Non-structural genes NS3 and NS5A of HCV genotype 3a were
ampliﬁed using the individual gene-speciﬁc primers (Table 1). The
ampliﬁed gene products of NS3 and NS5A are shown in Figure 1.
NS3 and NS5A were conﬁrmed by sequencing and submitted to
GenBank.
3.2. Construction of plasmids
To check the expression of the HCV genotype 3a non-structural
genes (NS3 and NS5A) and to examine their association with the
p53 gene, mammalian expression vectors were constructed
(Figure 2). In this study, the pcDNA3.1 mammalian expression
vector was used. The ampliﬁed genes were digested with speciﬁc
restriction enzymes and then cloned into the mammalian
expression vector pcDNA3.1 within respective restriction sites.
Successful pcDNA3.1/NS3 and pcDNA3.1/NS5A clones were
conﬁrmed by restriction digestion (Figure 3). The cytomegalovirus
(CMV) promoter is present in the pcDNA3.1 vector, which provides
an effective means to transduce the eukaryotic cells for transient
and stable expression studies.and (b) pcDNA3.1/NS5A protein coding construct.
Figure 3. Digestion of non-structural genes. Lane M: 1-kb marker; lanes 1–9: positively digested NS3-encoding clones; lanes 10–17: positively digested NS5A-encoding
clones.
Figure 5. RT-PCR to characterize NS5A-producing cell lines. Lane M: 1-kb marker;
lanes 1 and 2: Huh-7 (negative control); lanes 3–5: NS5A; lane 6: negative control.
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genes of 3a genotype
For the establishment of stable cells harboring NS3 and NS5A
genes, the Huh-7 cells were transfected with linearized expression
vectors using lipofectamine reagent. At 24 h post-transfection,
selection was applied to the transfected cells by growing them in
the presence of 1 mg/ml of G418. The cells were grown at this
concentration for about 4 weeks; most of the cells were unable to
develop resistance against G418. The G418-resistant colonies
isolated were selected and grown as individual cell lines at a
concentration of 500 mg/ml. The individually grown cell lines
showed some variation in growth rate.
3.4. Detection of NS3 and NS5A RNA in Huh-7 harboring 3a
subgenomic replicons through RT-PCR
To detect the presence of NS3 and NS5A RNA in transfected
G418-resistant cells, total RNA was extracted from the individually
grown cell lines of the respective HCV gene and untransfected
Huh-7 cells (control cells). Extracted RNA was reverse-transcribed
into cDNA using reverse transcriptase enzyme (MMLV) andFigure 4. RT-PCR to characterize NS3-producing cell lines. Lane M: 1-kb marker;
lanes 1 and 3: NS3; lanes 2 and 4: Huh-7 (negative control); lane 5: positive control.gene-speciﬁc primers. cDNA was further processed for ampliﬁca-
tion of NS3 and NS5A utilizing the corresponding gene-speciﬁc
primers. The approximate size of the HCV NS3 gene was 1953 bp
(Figure 4) and of the NS5A gene was 1356 bp (Figure 5).Figure 6. Analysis of protein (NS3) through Western blot: Western blot of NS3
protein detected using NS3-speciﬁc antibodies. Lanes 1–5: HCV NS3 protein
expressing stable cell line; lanes 6 and 7: Huh-7 (negative control).
Figure 7. Analysis of protein (NS5A) through Western blot: Western blot of NS5A
protein detected with NS5A-speciﬁc antibodies. Lane 1: Huh-7 cells (negative
control); lanes 2–5: HCV NS5A protein expressing stable cell lines.
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For the conﬁrmation of NS3 and NS5A protein expression in
Huh-7 cell lines, we isolated total proteins from Huh-7 comprising
HCV clones (NS3 and NS5A) and performed Western blot. After
Western blotting, speciﬁc bands were seen for NS3 of about 68–70
kDa and for NS5A of about 58 kDa, as shown in Figures 6 and 7,
respectively. Untransfected Huh-7 cells were used as a control.
3.6. Subcellular localization pattern of NS3 and NS5A protein
For direct visualization of HCV NS3 and NS5A expressed
proteins in HCV replicating Huh-7 cells, we performedFigure 8. Immunoﬂuorescence assay. 1: staining with FITC; 2: counterstaining with DA
assay of NS5A.immunostaining of stably expressing cell lines using the gene-
speciﬁc antibodies of relevant individual genes. The results
showed that the subcellular localization pattern of NS3 protein
was localized to the cytoplasm (Figure 8), while NS5A was also
localized to the cytoplasm. Findings also indicated that proteins
might have a leaky expression, because proteins were visualized
on the surface of the cells as well. Counterstaining conﬁrmed that
the cells were alive and successfully expressing the required genes
NS3 and NS5A of HCV genotype 3a.
3.7. The interaction of NS3 and NS5A with p53 in HCV subgenomic
replicon harboring cells
To determine whether the NS3 and NS5A expressed in
perspective of HCV replication interacted with p53, we used the
Huh-7 cells stably expressing NS3 and NS5A subgenomic replicons
and studied their interaction with p53. p53 was co-transfected in
stably expressing NS3 and NS5A cells lines with pcDNA3.1/myc-
his/p53. Protein expression was detected using anti-p53 anti-
bodies, and untransfected Huh-7 cells were used as control.
Western blot analysis revealed that the NS3 and NS5A interacted
efﬁciently with p53, because expression of p53 was higher in
control Huh-7 cells as compared to the HCV harboring cells (NS3
and NS5A), as shown in Figure 9. The results suggested that NS3
and NS5A full-length may interact physically or functionally and
sequester the p53 protein, thus inhibiting its expression.
4. Discussion
Several HCV proteins are linked to the restraining of important
host cell cycle proteins responsible for controlling the apoptotic
mechanism.17 The viral proteins are able to translocate to the cell
nucleus and to control these cell cycle proteins. Many studies have
reported the speciﬁc molecular types, the subcellular localization,
and particular domains of proteins inﬂuencing the oncogenicP-I; 3: merged. (a) Immunoﬂuorescence assay of NS3, and (b) immunoﬂuorescence
Figure 9. Analysis of the interaction of NS3 and NS5A proteins with p53. Lane 1:
p53; lane 2: p53 + NS5A; lane 3: NS5A; lane 4: p53 + NS3; lane 5: NS3; lane 6: Huh-7
(negative control).
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(HCC) is a chronic HCV infection.19 Studies have shown that one
mechanism of hepatic oncogenesis is the interaction between the
HCV oncogenic proteins and factors that either control cell
proliferation or inhibit their apoptosis, while other studies have
also conﬁrmed that some viral proteins physically or functionally
interact with the products of suppressor genes leading to the
development of primary HCC.17
No reliable and efﬁcient model or system is currently available
for the ampliﬁcation of viral particles, which limits the design and
development of drugs and vaccines against HCV.20 The only
currently available treatment for HCV is interferon therapy, either
alone or in combination with ribavirin.20–23 Novel therapeutic
strategies and the development of a vaccine are urgently required.
The lack of a robust cell culture system for the replication of the
virus has been found to be a hindrance in the study of the role of
many important viral proteins in viral disease progression.24 This
problem has been overcome, in part, by the development of
subgenomic replicas derived from different HCV genotypes.25
These replicas have been established in the human hepatoma cell
line and display sustained replication of the required viral genes in
the cytoplasm of human cell lines.26,27 These cell culture systems
are very simple and useful in the study of the mechanisms of HCV
pathogenicity in general.28 Such studies have been conducted in
various parts of the world to study the role of viral proteins in
disease progression,29–32 but as the HCV genome exhibits high
variation in the genes at both the local and global level, the already
existing systems cannot be used to study the role of viral proteins
in disease progression.33 The availability of a cell culture system is
a critical prerequisite to the study of the replication cycle of a virus
and to devise strategies for prophylactic and therapeutic inter-
ventions.34
In the current study, we successfully established stable cell
lines using the liver hepatoma cell line Huh-7, which effectively
expressed the non-structural protein NS3 and NS5A genes from
local Pakistani genotype 3a isolates, and also studied the role of
these expressed proteins in apoptosis. In this study, Western blot
conﬁrmed the protein expression of NS3 and NS5A in Huh-7 cells
lines in accordance with previously published reports.17,35 Our
immunoﬂuorescence analysis revealed that the protein is mainly
present in the cytoplasm of the cells. This study conﬁrms the
earlier studies in which cultured cells or in vivo protein has alsobeen observed in the cytoplasm of the infected hepatocytes.12,17
The study of immunoﬂuorescence is also signiﬁcant for the
detection and localization of HCV proteins in cells and in tissues for
diagnostic purposes and for the clinical management of HCV. It is
also helpful for the elucidation of viro-pathological mechanisms.36
Apoptosis is the main mechanism of defense against viral
infections.37 Among the many mechanisms, apoptosis is the best
characterized process in which p53 plays many diverse func-
tions.38 Genome stability/integrity is maintained by p53.12 More
than 10 million people with tumors have either abnormal p53 or
inactivated p53.38 It is also reported that the p53 function is
sequestered by other signaling components or the pathway of p53
is altered.39
In the present study we reported the relationship of HCV
genotype 3a NS3 and NS5A proteins of local Pakistani isolates with
the p53 protein, for the ﬁrst time. Western blot conﬁrmed that the
expression of the p53 gene was down-regulated in Huh-7 stable
cell lines expressing the HCV NS3 and NS5A subgenomic replicons.
There are several reasons for the down-regulation of p53 protein.
The NS3 and NS5A proteins might bind with the p53 protein in the
cytoplasm, because the proteins are expressed in cytoplasm, as
seen clearly in the immunoﬂuorescence analysis. The p53 protein
was also seen in cytoplasm because it was transiently expressed in
cells from an exogenous source. The association of p53 with NS3
and NS5A proteins of HCV genotype 1 has also been examined,40
and the formation of complexes of p53 with NS3 and NS5A proteins
in the cytoplasm has been validated.12,17 According to Lan et al.,
p53-mediated apoptosis is inhibited by the viral proteins, so it
might be conﬁrmed that the NS3 and NS5A proteins of HCV
genotype 3a may cooperate with p53 resulting in the sequestration
of p53 into the cytoplasm and the inhibition of p53-induced
apoptosis in HCV infections.12 This inhibition of p53 via viral genes
might be signiﬁcant in carcinogenesis. Previously published
reports have also conﬁrmed that the normal function of p53
protein is inhibited by the viral proteins.38,41
It is recommended that in the design of anti-cancer drugs, p53 is
an ideal target for the diagnosis and treatment of HCV. The
available cell culture system for HCV genotype 3a can be used to
study and design novel molecules, peptides, and vaccines against
not only the viral proteins but also against wild-type or mutant
p53. The management of clinical HCV patients can be improved by
the use of newly developed therapeutic strategies, along with the
routinely used therapeutic drugs.
In conclusion, this study is novel in that we focused on local
HCV genotype 3a, as no such study has been performed previously
in Pakistan on the relationship between the NS3 and NS5A proteins
of HCV genotype 3a of local isolates and p53 in a model system. For
the development of new therapeutic strategies and to improve
existing therapies, the developed model system is required for the
screening of antiviral drugs, not only for local genotypes, but also
for other existing genotypes.
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